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Abstract
Background: Visceral fat produces several hormones and cytokines associated with carcinogenesis and tumor
progression. Herein, we investigated the association between visceral adiposity and target-gene mRNA expression
in patients with localized small clear-cell renal-cell carcinoma (ccRCC).
Methods: We included 200 patients with localized clinical T1a stage ccRCC who had undergone nephrectomy from
November 2018 to November 2020 in a prospective clinical trial (NCT03694912). Visceral, subcutaneous, and total
adipose tissue in these patients was measured via preoperative computerized tomography of the mid-third lumbar
vertebra region. We then examined the association between adiposity and the mRNA levels of PBRM1, BAP1, SETD2,
KDM5C, FOXC2, CLIP4, AQP1, DDX11, BAIAP2L1, and TMEM38B in matched frozen tumor tissues and plasma samples.
Results: Upon the stratification of patients into quartiles according to their relative visceral adiposity, high visceral
adiposity was found to be significantly associated with low ISUP grade (P = 0.004). Multivariate logistic regression
analysis revealed a significant association between frozen tissue DDX11 expression and high visceral adiposity (OR
0.676, 95% CI 0.587–0.779, P < 0.001). Moreover, frozen tissue DDX11 expression was significantly associated with
high ISUP grade (OR 1.556, 95% CI 1.223–1.981, P < 0.001). The frozen tissue mRNA expression of DDX11 was
identified as a biomarker for visceral adiposity and cancer aggressiveness.
Conclusions: The results obtained herein will aid in inferring the aggressiveness of small ccRCCs, represented by
ISUP nuclear grade, in clinical practice. Our findings indicated that DDX11 and visceral fat play active roles in small
ccRCC. These roles should be examined in future studies for the possible use of DDX11 and visceral fat as
prognostic biomarkers in the treatment of patients with ccRCC.
Trial registration: ClinicalTrials.gov, NCT03694912, Registered 3 October 2018.
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Background
Renal-cell carcinoma (RCC) is the sixth and tenth most
common type of cancer in men and women worldwide,
respectively [1]. Clear-cell RCC (ccRCC) represents the
most prevalent type of RCC, and it is characterized by
mutations in genes governing the hypoxia signaling
pathway. Several studies have identified specific genetic
variances, and possible biomarkers for ccRCC, leading to
therapeutic innovations [2]. However, the tumor biology
of most commonly identified masses, which are ≤ 4 cm
in diameter and classified as small renal masses (SRMs),
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is poorly understood [3, 4]. A wide variety of therapeutic
modalities is used against SRMs, including surgical
tumor resection, ablation, as well as active surveillance
in some instances. Therefore, understanding the molecu-
lar characteristics and pathogenesis of SRMs is import-
ant for identifying specific biomarkers and selecting the
optimal therapeutic options in clinical settings [4].
Although obesity represents a well-established risk fac-
tor regarding RCC [5, 6], the detailed association be-
tween obesity and the prognosis of RCC patients is still
controversial and unclear. Some studies have reported
improved prognoses in overweight patients [6–12],
whereas other studies have reported no association be-
tween the clinical course of RCC and body weight [13,
14]. Regarding SRMs, the prognosis of RCC is inversely
proportional to the body mass index (BMI), indicating
that the tumor biology of SRMs is distinct from that of
non-SRMs.
Previous studies have mostly employed BMI as a
measure of obesity; however, BMI cannot be used to dis-
tinguish between fat, muscle, and bone. Furthermore,
BMI does not provide any information on fat distribu-
tion. The measurement of visceral fat can be used to as-
sess true obesity because visceral fat is the largest
endocrine organ in the body, producing several hor-
mones and cytokines related to carcinogenesis and
tumor progression [15].
Previously, we found that several potential prognostic
biomarkers are considerably up- or downregulated in
ccRCC, and can be used to identify the aggressive clin-
ical T1-stage [16, 17]. Total RNA sequencing data of 24
ccRCC patients (12 patients each with and without
aggressive characteristics) revealed 10 genes highly up-
regulated or downregulated associated with aggressive
disease. Among these 10 genes, DDX11 was significantly
upregulated in aggressive ccRCC and was associated
with low cancer-specific survival and high recurrence
rate [17]. In this study, we aimed to determine the asso-
ciation between visceral adiposity and the mRNA
expression of potential biomarkers using frozen tumor
tissues and preoperative plasma of patients with small
ccRCC. The present study presents information regard-
ing the development of rapid and straightforward tech-
niques for the evaluation of the aggressiveness of small
ccRCCs in clinical practice.
Materials and methods
Patients and tissues
All procedures involving human participants were per-
formed in accordance with the ethical standards of the
institutional and/or national research committee as well
as the 1964 Helsinki Declaration and its later amend-
ments or comparable ethical standards. The study was
approved by the Institutional Review Board of the
Yonsei University Health System (project no: 4-2018-
0753). Written informed consent was obtained from all
patients, and the manuscript does not contain any per-
son’s data in any form.
The present study included 200 patients with small lo-
calized ccRCC (≤ 4 cm, pT1aN0M0), who were treated
via nephrectomy only, and for whom frozen tumor tis-
sues and matching preoperative plasma samples were
available from a prospective study (ClinicalTrials.gov
Identifier: NCT03694912) conducted between November
2018 and November 2020.
The inclusion criteria used were as follows: (1) localized
small ccRCC (≤ 4 cm, pT1aN0M0); (2) availability of in-
formation on preoperative height and weight; (3) availabil-
ity of preoperative computed tomography (CT) data and
follow-up for more than 1 year; and (4) no neoadjuvant or
adjuvant systemic therapy. Clinicopathological data, in-
cluding age, sex, BMI, and tumor size, were recorded for
each patient. All tumors were reviewed according to the
2016 World Health Organization (WHO) classification
[18] and International Society of Urologic Pathologists
(ISUP) grading [19]. Grades 1 and 2 were considered as
low-grade disease, while grades 3 and 4 were considered
as high-grade disease. Minimum four slides were reviewed
for each case in order to minimize bias from intratumoral
heterogeneity (ITH). Tumor grade was blindly reviewed
by three independent pathologists, in order to minimize
the inter-pathologist reliability. For a consensus diagnosis,
at least 2 of the 3 pathologist’ diagnoses had to agree. Di-
ameters of the primary tumors were obtained via CT im-
aging. Collected tumor tissues and plasma samples were
stored in liquid nitrogen and – 80 °C until total RNA ex-
traction. All PCR samples were analyzed at the same time.
We assessed the expression levels of six genes (PBRM1,
BAP1, SETD2, KDM5C, FOXC2, and CLIP4) reportedly
associated with ccRCC, and four genes (AQP1, DDX11,
BAIAP2L1, and TMEM38B) examined in our previous
study involving RNA-seq analysis of aggressive ccRCC in
clinical T1 stage [16, 17].
Adiposity measurement
As shown in Fig. 1, the contents of visceral adipose tis-
sue (VAT), subcutaneous adipose tissue, and total adi-
pose tissue were measured via preoperative CT of the
mid-third lumbar vertebra region using Aquarius iNtu-
ition Viewer, version 4.4.12 (TeraRecon, Foster City, CA,
USA) with patients in a supine position. Preoperative
CT was performed within 1 month before the surgery in
order to minimize the change in body fat tissue over
time. Previous studies have consistently used mid-third
lumbar level for CT-defined image analysis [20]. Differ-
ent body compositions were evaluated using predefined
Hounsfield unit (HU) thresholds: − 190 to − 30 HU for
subcutaneous adipose tissue, and − 150 to − 50 HU for
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VAT [20]. VAT% was calculated using the formula
VAT% = [VAT/total adipose tissue] × 100 [20].
Blood sample processing
Peripheral blood was collected from each participant, ali-
quoted into ethylenediaminetetraacetic acid (EDTA)-
coated tubes, and centrifuged at 1600×g for 10 min at 4
°C. The plasma was then carefully transferred into new
tubes and further centrifuged at 4000×g for 10 min at 4
°C and stored at – 80 °C until further analysis.
RNA extraction and reverse transcription-quantitative
polymerase chain reaction (RT-qPCR)
Total RNA was extracted from frozen tissues and plasma
samples using TRIzol (Ambion, Life Technologies,
USA). RNA isolated from 1 mL of plasma was dissolved
in 20 μL of DEPC-treated water. The quantity and qual-
ity of RNA were assessed using a Nanodrop spectropho-
tometer (NanoDrop ND-1000, Thermo Scientific,
Wilmington, DE, USA). Precisely 1 μg per sample was
reverse-transcribed into first-strand cDNA using an iN-
tRon Maxime RT PreMix (Cat No. 25082; Intronbi,
Seongnam, South Korea), following the manufacturer’s
protocol. qPCR was performed using Power SYBR®
Green Master Mix (Thermo Fisher, Cat No. A25742,
USA) in a 10-μL reaction volume consisting of 5 μL of
SYBR Green master PCR mix, 1 μL each of the forward
and reverse primers (10 pmol), 1 μL of the diluted
cDNA template, and UltraPureTM distilled water (Invi-
trogen, NY, USA). The conditions for amplification are
listed as follows: initial denaturation at 95 °C for 10 min;
40 cycles of denaturation at 95 °C for 15 s, annealing at
58 °C for 60 s, and elongation at 72 °C for 60 s; and final
elongation at 72 °C for 5 min. qPCR was performed on
an ABI StepOnePlus Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). All measurements
were conducted using GAPDH as the reference gene to
normalize the relative expression levels of the target
genes. PCR primer sequences are shown in Table S1.
The relative gene expression was analyzed using the
2–ΔΔCT method, and the results are expressed as per-
centage change compared to the control values. At least
three replicates of RT-qPCR experiments were per-
formed, and the results were analyzed by a blinded
investigator.
Statistical analyses
Data are presented as the means ± standard deviations
or median (interquartile ranges) for continuous vari-
ables, and as percentage for categorical variables. Locally
weighted scatterplot smoothing curves and Pearson’s
correlation coefficient were used to assess the relation-
ship between BMI and total adipose tissue, subcutaneous
adipose tissue, VAT, or VAT%. High visceral adiposity
was defined as a VAT level higher than the median VAT
level. For univariate analysis, Wilcoxon test, Student’s t
test, or one-way analysis of variance was used to com-
pare continuous variables, and chi-square test or Fisher’s
exact test was used to compare categorical variables.
Multivariate logistic regression analyses were performed
to identify predictors of high visceral adiposity and high
ISUP grade, and odds ratios (ORs) with 95% confidence
intervals (CIs) were calculated. SPSS software version
23.0 (IBM Corp., Armonk, NY, USA) was used for all
statistical analyses. All statistical tests were two-tailed. P




The clinicopathological features of the study population
(200 patients) are listed in Table 1. The median patient
age was 52.0 years, and 76.5% of the patients were men.
The median BMI was 24.8 kg/m2, and one (0.5%) patient
was classified as underweight (less than 18.5 kg/m2), 101
(50.5%) as normal weight (18.5 to 24.9 kg/m2), 85
(42.5%) as overweight (25 to 29.9 kg/m2), and 13 (6.5%)
as obese (30 kg/m2 or greater) according to the WHO
Fig. 1 Computed tomography (CT) analysis of visceral and subcutaneous adipose tissue. Measurement of a visceral adipose tissue (VAT), b
subcutaneous adipose tissue (SAT), and c total adipose tissue (TAT) by CT analysis software for a representative patient
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BMI cutoff points [21]. The median tumor size was 2.0
cm, and 84 (42.0%) tumors were classified as high-grade.
The prevalence of hypertension, diabetes, and
hypercholesterolemia in the patient population was
36.0%, 10.0%, and 8.0%, respectively (Table 1). As shown
in Fig. 2, the total adipose tissue content [Pearson’s
correlation coefficient (r) = 0.505, P < 0.001)] and the sub-
cutaneous adipose tissue content (r = 0.536, P < 0.001)
were significantly correlated with BMI. The VAT content
(r = 0.274, P < 0.001) demonstrated significant correla-
tions with BMI, however, VAT% (P = 0.207) did not. Age,
hypertension, diabetes status, hypercholesterolemia,
smoking status, and alcohol consumption differed signifi-
cantly between men and women enrolled in the study
(Table 1). Apart from subcutaneous adipose tissue, the
adiposity variables, BMI, total adipose tissue, VAT, and
VAT% were all significantly higher in men than in
women.
Clinicopathological characteristics according to VAT
Patients were stratified into quartiles (Q1 to Q4) accord-
ing to the relative VAT contents (Table 2). High VAT
content at diagnosis was associated with the male sex,
an increased BMI, an increased prevalence of hyperchol-
esterolemia, current smoking and alcohol status, as well
as a low ISUP grade. Although significant differences
were found among different VAT quartiles in terms of
age, tumor size, prevalence of hypertension, they did not
show any tendency.
Expression of target genes in frozen tissues and plasma
according to high visceral adiposity
The relative mRNA levels of DDX11 in the frozen tissue
and plasma were significantly lower in patients with high
visceral adiposity, revealed using univariate analysis (P <
0.001 and P = 0.016, respectively) (Table 3). Multivariate
logistic regression analysis of 10 target gene expressions
from frozen tissue and plasma reported the significant
association in frozen tissue DDX11 expression according
to high VAT (OR 0.676, 95% CI 0.587–0.779, P <
0.001) (Table 3). FOXC2 and AQP1 expression in frozen
tissue were also significantly associated with high VAT
in multivariate logistic regression analysis (FOXC2, OR
Table 1 Clinicopathological characteristics of the study population according to gender
Total (n = 200) Men (n = 153; 76.5%) Women (n = 47; 23.5%) P
Median age (range) 52.0 (43.0–60.8) 50.0 (42.0–54.0) 66.0 (60.0–68.0) < 0.001
Median tumor size (cm) (range) 2.0 (1.4–2.9) 2.0 (1.4–2.8) 2.1 (1.4–3.6) 0.275
Median BMI (kg/m2) (range) 24.8 (23.5–27.7) 26.7 (24.2–28.6) 23.0 (21.9–24.2) < 0.001
Median TAT (mm2) (range) 29,205 (24,937–37,647) 31,005 (26,140–39,174) 26,400 (20,232–27,316) < 0.001
Median SAT (mm2) (range) 13,268 (10,127–17,695) 13,422 (10,127–18,016) 13,268 (11,218–17,042) 0.609
Median VAT (mm2) (range) 15,982 (11,302–19,879) 18,244 (14,495–20,584) 10,176 (4626–14,048) < 0.001
Median VAT% (range) 51.4 (42.9–62.5) 55.0 (48.5–64.4) 40.7 (31.8–51.4) < 0.001
No. comorbid conditions, n (%)
Hypertension 72 (36.0%) 46 (30.1%) 26 (55.3%) 0.002
Hypercholesterolemia 16 (8.0%) 8 (5.2%) 8 (17.0%) 0.026
Diabetes 20 (10.0%) 11 (7.2%) 9 (19.1%) 0.025
No. smoking status, n (%)
Never 75 (37.5%) 28 (18.3%) 47 (100.0%) < 0.001
Former 70 (35.0%) 70 (45.8%) 0 (0.0%)
Current 55 (27.5%) 55 (35.9%) 0 (0.0%)
No. alcohol status, n (%)
Never 69 (34.5%) 30 (19.6%) 39 (83.0%) < 0.001
Former 40 (20.0%) 40 (26.1%) 0 (0.0%)
Current 91 (45.5%) 83 (54.2%) 8 (17.0%)
No. ISUP grade, n (%)
Low-grade (1–2) 116 (58.0%) 105 (68.6%) 11 (23.4%) < 0.001
High-grade (3–4) 84 (42.0%) 48 (31.4%) 36 (76.6%)
Data are presented as medians (interquartile ranges) for continuous variables and as percentage for categorical variables. P values from the chi-square test or
Fisher's exact test were used to calculate mean differences for categorical variables and those from Wilcoxon test were used to calculate mean differences for
continuous variables. BMI body mass index, SAT subcutaneous adipose tissue, TAT total adipose tissue, VAT visceral adipose tissue, VAT% percentage of visceral
adipose tissue
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0.969, 95% CI 0.948–0.989, P = 0.003; AQP1, OR 0.410,
95% CI 0.212–0.793, P = 0.008) (Table 3).
When we included the clinicopathological parameters
and the mRNA expression of target genes that were sig-
nificantly associated with VAT contents, the univariate
logistic regression analysis revealed that gender, BMI,
the prevalence of hypercholesterolemia, smoking and al-
cohol status, DDX11 expression in frozen tissue, and
ISUP score were significantly associated with high vis-
ceral adiposity (Table 4). Multivariate logistic regression
analysis revealed that frozen tissue DDX11 levels (OR
0.816, 95% CI 0.706–0.943, P = 0.006), and ISUP (OR
0.245, 95% CI 0.061–0.974, P = 0.046) were significantly
associated with high visceral adiposity (Table 4).
Expression of target genes in frozen tissues and plasma
according to high ISUP grade
The relative mRNA level of DDX11 in the frozen tissue
was significantly higher in patients with high ISUP
grade, revealed using univariate analysis (P < 0.001)
(Table 5). Multivariate logistic regression analysis of 10
target gene expressions from frozen tissue and plasma
reported the significant association in frozen tissue
DDX11 expression according to high ISUP grade (OR
1.556, 95% CI 1.223–1.981, P < 0.001) (Table 5).
Expression of DDX11 in frozen tissues according to high
visceral adiposity and high ISUP grade in males and
females
The separate analysis of males and females using logistic
regression was performed due to the discrepancy of fat
distribution between males and females. The results
showed that DDX11 expression of frozen tissue for both
significantly correlated with VAT (P < 0.001) and ISUP
nuclear grade (P < 0.001) in males. Same results were
also reported for females, showing that DDX11 expres-
sion of frozen tissue for both significantly correlated
with VAT (P = 0.001) and ISUP nuclear grade (P =
0.004).
Discussion
In the present study, we identified the frozen tissue
mRNA levels of DDX11, which is involved in cellular
growth and division, as an independent prognostic factor
for high visceral adiposity even after adjusting for
Fig. 2 Correlation between body mass index (BMI) and adipose tissue parameters. Correlation between body mass index (BMI) and a total
adipose tissue (TAT), b subcutaneous adipose tissue (SAT), c visceral adipose tissue (VAT), and d VAT%. Locally weighted scatterplot smoothing
curves (blue line) were fitted in plots
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clinicopathological parameters that are significantly as-
sociated with adiposity. To the best of our knowledge,
this is the first study to investigate the association be-
tween the expression of genes potentially involved in
ccRCC and adiposity, as well as to use visceral adiposity
as a marker to infer the aggressiveness of small ccRCC.
BMI increases the relative risk for RCC [22]. However,
the association between BMI and RCC prognosis re-
mains controversial. Prior studies have mainly reported
the proportional associations between BMI and RCC
prognosis, whereas inverse, flat, or null associations have
also been reported [23]. The inconsistencies among the
results reported by these studies may be attributed to
the use of BMI as a surrogate marker for obesity. Among
various types of adipose tissue, VAT is the largest endo-
crine organ and produces hormones and cytokines that
are related to carcinogenesis and tumor progression
[15]. Subcutaneous adipose tissue and VAT share scant
functional similarities other than their efficiency in en-
ergy storage [24]. VAT releases high levels of adipokines
that are involved in inflammation and angiogenesis, in-
cluding interleukin-6, vascular endothelial growth factor,
and plasminogen activator inhibitor 1 [24]. In our study,
BMI was not significantly correlated with VAT,
indicating that the use of BMI would not provide con-
sistent results in assessing the association between obes-
ity and RCC prognosis. Among anthropometric
measurements, the VAT content measured via CT has
recently been examined for its utility in predicting the
risk of cancer.
Five studies have examined the VAT content in pa-
tients with localized and/or advanced RCC [25]. Among
these, three reported that low VAT contents are associ-
ated with poor prognosis in patients with RCC [25], and
one study reported no association between VAT con-
tents and overall mortality [26]. Park and colleagues re-
ported that the lowest and the highest vs. the second
quartiles of the VAT% are associated with a higher risk
of recurrence [23]. Most studies have reported better
prognosis in patients with high obesity, especially in
those with localized SRMs [11, 23]. Moreover, Parker
et al. reported that, in terms of aggressiveness, high BMI
is associated with the presentation of a less aggressive
form of RCC [9].
Among 28 studies that analyzed the body composition
regarding the clinical outcomes of RCC in October
2016, 9 studies used fat index, which is the fat area di-
vided by the height of the patients [25]. Since 19 studies
Table 2 Clinicopathological characteristics according to visceral adipose tissue content
Q1 Q2 Q3 Q4 P
Median age (range) 57.5 (51.0–62.0) 60.0 (46.0–68.0) 46.0 (39.0–57.3) 51.0 (42.0–54.0) < 0.001
No. gender, n (%)
Male 24 (48.0%) 33 (66.0%) 46 (92.0%) 50 (100.0%) < 0.001
Female 26 (52.0%) 17 (34.0%) 4 (8.0%) 0 (0.0%)
Median tumor size (cm) (range) 1.8 (1.2–2.8) 2.5 (1.8–3.6) 1.6 (1.4–1.7) 2.1 (1.2–2.9) < 0.001
Median BMI (kg/m2) (range) 22.9 (21.9–24.6) 24.4 (23.0–26.6) 27.7 (24.1–29.0) 27.1 (25.1–29.2) < 0.001
No. comorbid conditions, n (%)
Hypertension 13 (26.0%) 26 (52.0%) 9 (18.0%) 18 (36.0%) 0.002
Hypercholesterolemia 0 (0.0%) 4 (8.0%) 4 (8.0%) 8 (16.0%) 0.034
Diabetes 8 (16.0%) 3 (6.0%) 6 (12.0%) 3 (6.0%) 0.261
No. smoking status, n (%) < 0.001
Never 35 (70.0%) 22 (44.0%) 12 (24.0%) 6 (12.0%)
Former 12 (24.0%) 22 (44.0%) 22 (44.0%) 14 (28.0%)
Current 3 (6.0%) 6 (12.0%) 16 (32.0%) 30 (60.0%)
No. alcohol status, n (%)
Never 28 (56.0%) 20 (40.0%) 15 (30.0%) 6 (12.0%) < 0.001
Former 7 (14.0%) 6 (12.0%) 9 (18.0%) 18 (36.0%)
Current 15 (30.0%) 24 (48.0%) 26 (52.0%) 26 (52.0%)
No. ISUP grade, n (%)
Low-grade (1–2) 10 (20.0%) 20 (40.0%) 46 (92.0%) 40 (80.0%) < 0.001
High-grade (3–4) 40 (80.0%) 30 (60.0%) 4 (8.0%) 10 (20.0%)
Data are presented as medians (interquartile ranges) for continuous variables and as percentage for categorical variables. P values from one-way analysis of
variance and chi-square test or Fisher’s exact test were used to determine mean differences for continuous and categorical variables, respectively, based on VAT
quartiles. BMI body mass index, SAT subcutaneous adipose tissue, TAT total adipose tissue, VAT visceral adipose tissue, VAT% percentage of visceral adipose tissue
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Table 3 Expression of target genes in patients with clear-cell renal-cell carcinoma characterized by high/low visceral adiposity
Low visceral adiposity High visceral adiposity Pa Pb
mRNA expression (× 100) (N = 100) (N = 100)
Frozen tissue
FOXC2 17.011 ± 33.556 7.896 ± 14.304 0.014 0.003
CLIP4 17.158 ± 32.455 9.365 ± 12.712 0.027 0.121
PBRM1 8.950 ± 11.257 7.032 ± 8.787 0.181 0.249
SETD2 1.476 ± 2.153 2.077 ± 2.316 0.059 0.759
BAP1 18.530 ± 59.910 1.649 ± 6.515 0.006 0.201
KDM5C 1.744 ± 2.704 1.954 ± 5.187 0.720 0.508
AQP1 1.283 ± 1.486 1.958 ± 0.981 < 0.001 0.008
DDX11 10.196 ± 10.477 1.890 ± 2.875 < 0.001 < 0.001
BAIAP2L1 3.007 ± 4.574 2.403 ± 3.139 0.277 0.051
TMEM38B 4.627 ± 7.711 7.055 ± 12.656 0.103 0.382
Plasma
FOXC2 16.708 ± 11.659 16.235 ± 8.215 0.740 0.705
CLIP4 16.848 ± 22.763 17.631 ± 22.080 0.805 0.895
PBRM1 2.452 ± 2.180 5.751 ± 41.896 0.417 0.099
SETD2 1.339 ± 1.690 2.346 ± 1.388 < 0.001 0.512
BAP1 98.325 ± 357.418 43.885 ± 244.658 0.210 0.633
KDM5C 13.468 ± 19.377 6.992 ± 9.286 0.003 0.776
AQP1 12.095 ± 19.380 8.017 ± 16.235 0.108 0.286
DDX11 5.484 ± 11.271 2.641 ± 2.657 0.016 0.081
BAIAP2L1 9.706 ± 15.835 4.965 ± 11.904 0.018 0.140
TMEM38B 17.087 ± 21.024 22.035 ± 33.570 0.213 0.523
Data are shown as the means ± standard deviations
aP values determined using Student’s t-test for univariate analysis
bP values determined using logistic regression for multivariate analysis
Table 4 Predictors of high visceral adiposity in clinical T1a clear-cell renal-cell carcinoma
Univariate Multivariate
OR (95% CI) Pa OR (95% CI) Pb
Clinical parameters
Gender (reference male) 0.055 (0.019–0.162) < 0.001 0.000 (0.000–0.000) 0.997
BMI (kg/m2) 1.496 (1.311–1.707) < 0.001 1.148 (0.957–1.376) 0.138
Hypercholesterolemia (vs. none) 3.273 (1.018–10.523) 0.047 3.042 × e10 0.996
Smoking (vs. never)
Former 3.353 (1.653–6.803) 0.001 0.284 (0.080–1.007) 0.051
Current 16.185 (6.650–39.392) < 0.001 2.406 (0.606–9.545) 0.212
Alcohol (vs. never)
Former 4.747 (2.055–10.964) < 0.001 1.854 (0.383–8.965) 0.443
Current 3.048 (1.575–5.895) 0.001 0.374 (0.109–1.290) 0.119
mRNA expression levels
DDX11 (frozen tissue) 0.785 (0.726–0.850) < 0.001 0.816 (0.706–0.943) 0.006
ISUP nuclear grade
(reference low-grade)
0.070 (0.034–0.142) < 0.001 0.245 (0.061–0.974) 0.046
aP values determined using logistic regression for univariate analysis
bP values determined using logistic regression for multivariate analysis. BMI body mass index
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used the fat area, we used it as well. However, there
could be some bias in using only the fat area, not ad-
justed to the height of the patients.
Although subcutaneous adipose tissue is not associ-
ated with perioperative outcomes and survival in RCC,
for other cancers, subcutaneous adipose tissue is report-
edly associated with cancer-survival outcomes. Taka-
masa et al. reported that high subcutaneous adipose
tissue volume in hepatocellular carcinoma is associated
with better survival outcomes when treated with trans-
catheter intra-arterial therapies [27]. Moreover, leptin
and adiponectin, which play a role in cancer biology, are
both influenced by VAT and the subcutaneous adipose
tissue [28, 29]. Therefore, although subcutaneous adi-
pose tissue is not significantly associated with aggressive
RCC, we should not overlook the unidentified import-
ance of the subcutaneous adipose tissue.
DDX11 expression, which is involved in cell-cycle
progression, is used to predict tumor aggressiveness in
clinically localized T1-stage ccRCC [16, 17]. Addition-
ally, the inhibition of DDX11 expression decreases the
proliferation rate of melanoma cells and induces
apoptosis [30]. In patients with lung adenocarcinoma,
upregulated DDX11 expression is associated with poor
prognosis [31].
Consistent with the results of previous studies, our
present study showed an inverse relationship between
high visceral adiposity and the expression of DDX11
mRNA in the frozen tissues. Previously, we showed
that aggressive ccRCC, such as that associated with
synchronous metastasis, recurrence, and/or cancer-
specific death, is also associated with the upregulated
expression of DDX11 mRNA in both plasma and fro-
zen tissues. Most studies showed that high VAT con-
tents are associated with improved prognosis; thus, we
suggest that less aggressive ccRCC is likely associated
with high VAT contents. The results obtained in our
present study indicated that non-aggressive ccRCC is
associated with high VAT contents and low expression
of DDX11. Based on these results, conservative thera-
peutic options, such as ablation and active surveil-
lance, would be prudent strategies for treatment of
patients with small ccRCC, a high VAT, and decreased
DDX11 expression.
Table 5 Expression of target genes in patients with clear-cell renal-cell carcinoma characterized by high/low ISUP nuclear grade
Low-grade High-grade Pa Pb
mRNA expression (× 100) (N = 116) (N = 84)
Frozen tissue
FOXC2 14.360 ± 29.842 9.820 ± 19.779 0.226 0.855
CLIP4 10.332 ± 15.012 17.307 ± 33.837 0.080 0.911
PBRM1 7.592 ± 8.283 8.543 ± 12.242 0.538 0.391
SETD2 2.615 ± 2.606 0.619 ± 0.633 < 0.001 0.095
BAP1 3.074 ± 12.171 19.778 ± 64.299 0.021 0.831
KDM5C 1.911 ± 4.806 1.763 ± 2.970 0.803 0.553
AQP1 2.337 ± 1.052 0.631 ± 0.903 < 0.001 0.117
DDX11 1.177 ± 2.103 12.763 ± 9.870 < 0.001 < 0.001
BAIAP2L1 3.155 ± 4.468 2.084 ± 2.931 0.042 0.448
TMEM38B 6.567 ± 12.125 4.838 ± 7.751 0.221 0.511
Plasma
FOXC2 16.649 ± 8.717 16.226 ± 11.721 0.770 0.490
CLIP4 16.241 ± 20.357 18.619 ± 24.948 0.460 0.333
PBRM1 5.672 ± 38.886 2.065 ± 1.880 0.397 0.538
SETD2 2.736 ± 1.488 0.610 ± 0.771 < 0.001 0.269
BAP1 26.289 ± 146.051 132.993 ± 435.106 0.033 0.520
KDM5C 6.804 ± 8.069 14.961 ± 21.136 0.001 0.964
AQP1 8.376 ± 16.698 12.376 ± 19.408 0.129 0.965
DDX11 3.545 ± 7.810 4.778 ± 8.911 0.311 0.953
BAIAP2L1 5.098 ± 12.002 10.425 ± 16.291 0.012 0.827
TMEM38B 21.343 ± 30.192 17.099 ± 24.749 0.277 0.950
Data are shown as the means ± standard deviations
aP values determined using Student’s t test for univariate analysis
bP values determined using logistic regression for multivariate analysis
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The underlying mechanism that links visceral adiposity
to the upregulation of DDX11 expression is unknown.
The pathogenesis of how DDX11 is involved in adipo-
genesis and cancer progression is undetermined al-
though some suggestions for the plausible mechanisms
might be possible. DDX11, a DNA-dependent ATPase
and helicase, plays an important role in the cohesion of
chromosome arms and centromeres [32]. The depletion
of DDX11 results in mitotic failure because the repli-
cated chromosomes fail to segregate after prometaphase
[32]. DDX11 expression may be associated with the G1–
S phase of the cell-cycle and the pathways involved in
DNA replication [32]. Recent studies suggest that adipo-
cyte differentiation, lipogenesis, and lipolysis are strongly
modulated by cell-cycle regulators, which control the
checkpoints for cell duplication [33]. Our results suggest
that DDX11, which is involved in cell-cycle regulation,
may be associated with VAT generation. Because the
exact pathways connecting cell-cycle regulation and
adiposity remain unknown, future studies should eluci-
date the mechanisms underlying visceral adiposity and
DDX11 expression. We are under in vitro experiments
on how DDX11 affects both adipogenesis and cancer
progression. This study suggested the possible mecha-
nisms linking VAT, DDX11, and tumor aggressiveness
and provided support for future studies including
in vitro experiments we are undergoing.
Although FOXC2 and AQP1 were not significantly
associated with ISUP nuclear grades, they were signifi-
cantly associated with VAT. FOXC2 and AQP1 were the
first to be identified as the significant genes associated
with ccRCC aggressiveness such as synchronous metas-
tasis and ccRCC-specific death in on our previous
studies [16, 17, 34]. Our group was the first to identify
FOXC2 as a biomarker of aggressive ccRCC [16, 34].
One study reported upregulation of FOXC2 in aggressive
ccRCC [34], while downregulation of FOXC2 in aggres-
sive ccRCC was observed in the subsequent study [16].
We believe that these differences might have resulted
from different definition of aggressiveness. Ahn et al. an-
alyzed the biomarkers that are associated with synchron-
ous metastasis [34], while Park et al. demonstrated the
biomarkers associated with a tumor exhibiting synchron-
ous metastasis, recurrence, or cancer-specific death, and
synchronous metastasis [16]. According to other studies,
the results are controversial as well, with one study
reporting upregulation of FOXC2 in association with
cancer metastasis and epithelial-mesenchymal transition
[35, 36], while other study reports FOXC2 upregulation
acts as a checkpoint to inhibit epithelial cell dedifferenti-
ation [37]. Although several studies have reported the
usefulness of urine AQP1, few studies reported analysis
of the frozen tissue AQP1 in RCC. Huang et al.
demonstrated that frozen tissue AQP1 expression was
significantly differed according to RCC subtype-specific
expression, and its expression level provided prognostic
information for ccRCC patients [38].
Our study was the first to evaluate the association be-
tween visceral adiposity and mRNA expression of target
genes. Moreover, our results enabled us to easily infer the
aggressiveness of ccRCCs using visceral adiposity calcu-
lated from preoperative CT without any invasive diagnos-
tic modalities. Although mutations in each of these kidney
cancer genes result in dysregulation of metabolic path-
ways, suggesting that kidney cancer is a disease of cell me-
tabolism [39], no studies have attempted to find the
association of gene expression or tumor aggressiveness of
ccRCC with metabolic factors such as adiposity. We be-
lieve that this study could be the cornerstone for the
ccRCC metabolism in association with biomarker expres-
sion and tumor aggressiveness.
Our study has a few limitations. First, the ITH of
primary tumors is a considerable problem, even in SRMs
[25]. ITH causes sampling bias in conventional needle
biopsies. Clinical trials are currently examining the use
of circulating tumor DNA in plasma to overcome the
limitations imposed by ITH. Second, we could not use
visceral adiposity and target-gene expression to predict
prognostic indexes, such as cancer-specific or
progression-free survival, in patients with ccRCC, owing
to the short follow-up period. Only one patient devel-
oped recurrence among the 200 patients included in this
study, and no other patients developed recurrence, me-
tastasis, or cancer-specific death. WHO/ISUP grading
system has several advantages over the former Fuhrman
grading system, that are easier to apply, more reprodu-
cible and clinically relevant with its relevance for prog-
nosis and serving as an alternative means of categorizing
tumors for future patient management [19, 40]. Since
high nuclear grade is currently the most important and
significant prognostic factor for predicting oncological
outcomes [41], we evaluated the association between the
expression of biomarkers and a high nuclear grade.
Third, the study population was relatively small. Future
studies should investigate the correlations among vis-
ceral adiposity, target-gene expression, and prognosis in
large populations of patients with ccRCC.
Conclusions
In the present study, we investigated the association
between visceral adiposity and target-gene mRNA ex-
pression in patients with localized small ccRCC. DDX11
mRNA levels in the frozen tissues and plasma are sig-
nificantly associated with high visceral adiposity. Quanti-
fying the VAT contents in preoperative CT scans will
enable us to infer the aggressiveness of small ccRCCs in
clinical practice. The role of DDX11 in the regulation of
VAT warrants further investigation in future studies.
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